BioLineRx Ltd. (BLRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

2.8800-0.1600 (-5.26%)

At close: 4:00PM EDT

2.8800 0.00 (0.00%)
After hours: 07:18PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Price Crosses Moving Average

View all chart patterns

Performance Outlook

Previous Close	3.0400
Open	2.9800
Bid	2.8800 x 800
Ask	2.9300 x 1800
Day's Range	2.8500 - 2.9800
52 Week Range	1.4000 - 6.3400
Volume	337,647
Avg. Volume	421,578

Market Cap	136.22M
Beta (5Y Monthly)	1.45
PE Ratio (TTM)	N/A
EPS (TTM)	-1.0950
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	14.50

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BLRX

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

BioLineRx Ltd.
Analyst Report: Quest Diagnostics IncorporatedQuest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of nearly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Rating
Fair Value
Economic Moat
3 days agoMorningstar

All

News

Press Releases

Research Reports

PR Newswire
BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a pharmacoeconomic study evaluating the cost-effectiveness of using investigational drug Motixafortide as a primary stem cell mobilization (SCM) agent on top of granulocyte colony stimulating factor (G-CSF), versus G-CSF alone, in multiple myeloma patients undergoing autologous stem cell transplantation (ASCT). The study was performed by the Globa
Insider Monkey
11 Best Stocks for Long Term Growth
In this article, we discuss the 11 best stocks for long-term growth. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Stocks for Long Term Growth. As the economy recovers post COVID-19, many investors see the surge in consumer spending and the expansion of the digital economy […]
PR Newswire
BioLineRx Reports Second Quarter 2021 Financial Results and Provides Corporate Update
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended June 30, 2021 and provides a corporate update.